182 related articles for article (PubMed ID: 35282099)
1. A clinical nomogram for predicting tumor regression grade in esophageal squamous-cell carcinoma treated with immune neoadjuvant immunotherapy.
Yu Y; Wang W; Qin Z; Li H; Liu Q; Ma H; Sun H; Bauer TL; Pimiento JM; Gabriel E; Birdas T; Li Y; Xing W
Ann Transl Med; 2022 Jan; 10(2):102. PubMed ID: 35282099
[TBL] [Abstract][Full Text] [Related]
2. Predictive model of postoperative pneumonia after neoadjuvant immunochemotherapy for esophageal cancer.
Wang W; Yu Y; Sun H; Wang Z; Zheng Y; Liang G; Chen P; Cheng J; Xu X; Yang F; Liu Q; Xing W
J Gastrointest Oncol; 2022 Apr; 13(2):488-498. PubMed ID: 35557590
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of albumin-bound paclitaxel combined with nedaplatin in neoadjuvant therapy for esophageal squamous cell carcinoma: A single-center retrospective observational study.
Chen J; Zhu J; Zhang Y; Wang W; Xia Y; Zhao J; Jiang T
Medicine (Baltimore); 2023 Mar; 102(9):e33157. PubMed ID: 36862884
[TBL] [Abstract][Full Text] [Related]
4. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.
Gao L; Hong ZN; Wu L; Yang Y; Kang M
Front Immunol; 2022; 13():1008681. PubMed ID: 36569913
[TBL] [Abstract][Full Text] [Related]
5. [Risk factor analysis on anastomotic leakage after laparoscopic surgery in rectal cancer patient with neoadjuvant therapy and establishment of a nomogram prediction model].
Jiang W; Feng MY; Dong XY; Dong SM; Zheng JX; Liu XM; Liu WJ; Yan J
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Aug; 22(8):748-754. PubMed ID: 31422613
[No Abstract] [Full Text] [Related]
6. Multidetector CT for Restaging Locally Advanced Esophageal Squamous Cell Carcinoma and Assessing Therapeutic Response to Neoadjuvant Chemotherapy.
Shi Y; Chen Y; Li X; Wang Z; Sun Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Feb; 39(1):133-139. PubMed ID: 28270296
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of systemic immune-inflammation index for pathological complete response in patients receiving neoadjuvant immunochemotherapy for locally advanced esophageal cancer.
Han W; Weng K; Zhang P; Hong Z
Front Surg; 2022; 9():1091601. PubMed ID: 36684142
[TBL] [Abstract][Full Text] [Related]
8. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
9. Pathologic Complete Response Prediction to Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Real-World Evidence from Integrative Inflammatory and Nutritional Scores.
Feng J; Wang L; Yang X; Chen Q; Cheng X
J Inflamm Res; 2022; 15():3783-3796. PubMed ID: 35832830
[TBL] [Abstract][Full Text] [Related]
10. A Novel Predictor of Pathologic Complete Response for Neoadjuvant Immunochemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma.
Yang Y; Xin D; Wang H; Guan L; Meng X; Lu T; Bai X; Wang F
J Inflamm Res; 2023; 16():1443-1455. PubMed ID: 37042015
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of a Radiomics Nomogram Model for Predicting Postoperative Recurrence in Patients With Esophageal Squamous Cell Cancer Who Achieved pCR After Neoadjuvant Chemoradiotherapy Followed by Surgery.
Qiu Q; Duan J; Deng H; Han Z; Gu J; Yue NJ; Yin Y
Front Oncol; 2020; 10():1398. PubMed ID: 32850451
[No Abstract] [Full Text] [Related]
12. Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer.
Ma R; Yuan D; Mo C; Zhu K; Dang C; Zhang Y; Yin J; Li K
Sci Rep; 2023 Apr; 13(1):6080. PubMed ID: 37055490
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a nomogram to predict pathological complete response in patients with locally advanced gastric adenocarcinoma treated with neoadjuvant chemotherapy in combination with PD-1 antibodies.
Li L; Chen G; Chen EY; Strickland MR; Zhao W; Zhang J; Li Z
J Gastrointest Oncol; 2023 Dec; 14(6):2373-2383. PubMed ID: 38196541
[TBL] [Abstract][Full Text] [Related]
14. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Hatogai K; Fujii S; Kojima T; Daiko H; Kadota T; Fujita T; Yoshino T; Doi T; Takiguchi Y; Ohtsu A
J Surg Oncol; 2016 Mar; 113(4):390-6. PubMed ID: 27100024
[TBL] [Abstract][Full Text] [Related]
16. The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study.
Xing W; Zhao L; Zheng Y; Liu B; Liu X; Li T; Zhang Y; Ma B; Yang Y; Shang Y; Fu X; Liang G; Yuan D; Qu J; Chai X; Zhang H; Wang Z; Lin H; Liu L; Ren X; Zhang J; Gao Q
Front Immunol; 2021; 12():772450. PubMed ID: 34938292
[TBL] [Abstract][Full Text] [Related]
17. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
[TBL] [Abstract][Full Text] [Related]
19. [Prediction of pathological remission of head and neck squamous cell carcinoma patients after neoadjuvant immunochemotherapy and construction of clinical model based on clinical features and inflammatory markers].
Lin QH; Yan SD; Zhang X; Chen SW; Li XY; Zhang Y; Zhang ST; Song M
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):357-365. PubMed ID: 38599643
[No Abstract] [Full Text] [Related]
20. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
